AU2019241803A1 - Compositions for preventing or treating cognitive impairment-related disease comprising mumefural - Google Patents

Compositions for preventing or treating cognitive impairment-related disease comprising mumefural Download PDF

Info

Publication number
AU2019241803A1
AU2019241803A1 AU2019241803A AU2019241803A AU2019241803A1 AU 2019241803 A1 AU2019241803 A1 AU 2019241803A1 AU 2019241803 A AU2019241803 A AU 2019241803A AU 2019241803 A AU2019241803 A AU 2019241803A AU 2019241803 A1 AU2019241803 A1 AU 2019241803A1
Authority
AU
Australia
Prior art keywords
mumefural
dementia
composition
cognitive impairment
memory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2019241803A
Other languages
English (en)
Inventor
Jihye BANG
Won Kyung Jeon
Min Soo Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Korea Institute of Oriental Medicine
Original Assignee
Korea Institute of Oriental Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Institute of Oriental Medicine filed Critical Korea Institute of Oriental Medicine
Publication of AU2019241803A1 publication Critical patent/AU2019241803A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/20—Inorganic substances, e.g. oligoelements
    • A23K20/24—Compounds of alkaline earth metals, e.g. magnesium
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/116—Heterocyclic compounds
    • A23K20/121—Heterocyclic compounds containing oxygen or sulfur as hetero atom
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/158—Fatty acids; Fats; Products containing oils or fats
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/174—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Animal Husbandry (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fodder In General (AREA)
AU2019241803A 2018-03-27 2019-03-05 Compositions for preventing or treating cognitive impairment-related disease comprising mumefural Abandoned AU2019241803A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020180035324A KR102037944B1 (ko) 2018-03-27 2018-03-27 무메푸랄을 포함하는 인지장애 관련 질환의 예방 또는 치료용 조성물
KR10-2018-0035324 2018-03-27
PCT/KR2019/002545 WO2019190069A1 (ko) 2018-03-27 2019-03-05 무메푸랄을 포함하는 인지장애 관련 질환의 예방 또는 치료용 조성물

Publications (1)

Publication Number Publication Date
AU2019241803A1 true AU2019241803A1 (en) 2020-11-19

Family

ID=68062313

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019241803A Abandoned AU2019241803A1 (en) 2018-03-27 2019-03-05 Compositions for preventing or treating cognitive impairment-related disease comprising mumefural

Country Status (6)

Country Link
US (1) US20210106550A1 (cg-RX-API-DMAC7.html)
EP (1) EP3789023A4 (cg-RX-API-DMAC7.html)
JP (1) JP2021519330A (cg-RX-API-DMAC7.html)
KR (1) KR102037944B1 (cg-RX-API-DMAC7.html)
AU (1) AU2019241803A1 (cg-RX-API-DMAC7.html)
WO (1) WO2019190069A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102301757B1 (ko) 2020-12-18 2021-09-13 서울대학교산학협력단 스트레스로 인한 기억력 감퇴 억제 및 학습 능력 향상을 위한 천연 혼합 조성물
CN115531368A (zh) * 2021-06-14 2022-12-30 谭文 R-氨基甲酸酯-β-苯乙醇胺类化合物治疗学习和记忆缺陷以及神经退行性疾病的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100525474B1 (ko) * 2003-10-07 2005-11-02 롯데제과주식회사 항스트레스 및 뇌기능 개선 효과를 가지는 가미사군자탕 함유 의약품
JP2005289940A (ja) * 2004-04-05 2005-10-20 Hiroko Ito フリーラジカル消去剤
RU2327480C1 (ru) * 2007-05-23 2008-06-27 Виктор Иванович Рощин Активный ингредиент лекарственного средства, лекарственное средство, фармацевтическая композиция и способ лечения больных с дементным синдромом
KR101144197B1 (ko) * 2009-03-31 2012-05-11 전남대학교산학협력단 신생혈관형성 억제제 및 이를 이용한 천연산물 항비만제
CN103237556B (zh) * 2010-10-04 2016-03-16 韩国韩医学研究院 包含乌梅提取物的用于预防或治疗痴呆的组合物
KR20140144785A (ko) 2013-06-11 2014-12-22 한국식품연구원 유자(Citrus junos Tanaka) 추출물을 유효성분으로 포함하는 기억력 및 학습 능력 증진용 조성물
KR101823892B1 (ko) 2014-03-10 2018-02-01 우석대학교 산학협력단 기억력 개선, 인지능력 개선, 치매 예방, 지연 또는 치료 효과를 나타내는 봉선화 추출물, 이를 유효성분으로 하는 약제학적 조성물, 이를 유효성분으로 포함하는 기능성 건강보조식품 및 봉선화 추출물의 제조방법
KR101837444B1 (ko) 2016-10-25 2018-03-13 한국 한의학 연구원 양지꽃 추출물을 유효성분으로 함유하는 인지기능 장애의 예방, 개선 또는 치료용 조성물

Also Published As

Publication number Publication date
KR102037944B1 (ko) 2019-10-29
KR20190113105A (ko) 2019-10-08
JP2021519330A (ja) 2021-08-10
EP3789023A1 (en) 2021-03-10
US20210106550A1 (en) 2021-04-15
WO2019190069A1 (ko) 2019-10-03
EP3789023A4 (en) 2022-03-30

Similar Documents

Publication Publication Date Title
Ji et al. Astaxanthin improves cognitive performance in mice following mild traumatic brain injury
KR101799829B1 (ko) 퇴행성 뇌질환의 예방 또는 치료 효과를 가지는 아커만시아 뮤시니필라 균주 및 이의 용도
US20190314425A1 (en) Akkermansia muciniphila strain having a prophylactic or therapeutic effect on a degenerative brain disease or metabolic disease and use thereof
US10821130B2 (en) Omega 3 fatty acids, no releasing compound and vitamin B12 as neuroprotectant in patients with no dementia
JP7809461B2 (ja) リポ多糖を用いた脳機能改善剤、食品及び医薬品
EP3444330B1 (en) Strain of genus agathobaculum having effects of preventing or treating degenerative brain diseases, and use thereof
JP7524294B2 (ja) 認知症ではない個体において認知的加齢を軽減する組成物の製造方法
CN107427485B (zh) 用于治疗焦虑症的中链脂肪酸及其甘油三酯
KR102527378B1 (ko) 2'-fl을 함유하는 도파민 감소로 말미암아 발생하는 질환의 개선, 예방 또는 치료용 조성물
EP3789023A1 (en) Composition for preventing or treating cognitive disorder-associated diseases, containing mumefural
DE102008064588A1 (de) Nahrungsergänzungsmittel auf der Basis von Pantothensäure
CN115381924A (zh) 一种用于神经修复的组合物及其制备方法和应用
US11607433B2 (en) Composition for preventing, improving, or treating autism spectrum disorders including Agathobaculum sp. strain as active ingredient
US11554162B2 (en) Pharmaceutical or food supplement preparation based on alpha-lactalbumin
KR102722498B1 (ko) 인지 기능 개선용 조성물 및 불안양 증상 개선용 조성물, 및 뇌 위축 억제용 조성물
US20100209527A1 (en) Composition for prevention or treatment of disease associated with production of autoantibody
JP2016524609A (ja) メントール及び/又はイシリンを用いるうつ病の処置又は予防
KR102301757B1 (ko) 스트레스로 인한 기억력 감퇴 억제 및 학습 능력 향상을 위한 천연 혼합 조성물
EP3388061A1 (en) Omega 3 fatty acids, no releasing compound, vitamin b12 and choline as neuroprotectant in patients with no dementia
JP7762980B2 (ja) エルゴチオネイン、またはセレノネインを用いる自閉症スペクトラム障害の治療方法
Gamaleldin et al. Nutrition and Brain Neurotransmitters
JP2024093340A (ja) 神経興奮抑制剤
CA3034187C (en) Omega 3 fatty acids and choline as neuroprotectant in patients with no dementia
KR20250145285A (ko) 릴메니딘을 포함하는 정서장애의 예방, 개선 또는 치료용 조성물
HK40051287A (en) Omega-3 fatty acid and choline in compositions and methods that attenuate cognitive aging in individuals who do not have dementia

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ COMPOSITIONS FOR PREVENTING OR TREATING COGNITIVE IMPAIRMENT-RELATED DISEASE COMPRISING MUMEFURAL

MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted